Recombinant Proteins
Product List
SERF2 Human
Small EDRK-Rich Factor 2 Human Recombinant
HRSP12 Human
Heat-Responsive Protein 12 Human Recombinant
SERPINC1 Human
Serpin Peptidase Inhibitor, Clade C Member 1 Human Recombinant
SERPINC1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
HSCB Human
HscB Iron-Sulfur Cluster Co-Chaperone Human Recombinant
HSCB is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
HUS1 Human
HUS1 Checkpoint Homolog Human Recombinant
HUS1 is fused to a 20 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
SET Human
SET Human Recombinant
IBSP Human, HEK
Integrin Binding Sialoprotein Human Recombinant, HEK
IBSP Human Recombinant produced in HEK293 Cells is a single, glycosylated polypeptide chain (17-317 a.a) containing a total of 307 amino acids and having a molecular mass of 34.3 kDa.
IBSP is fused to a 6 amino acid His-tag at C-terminus and is purified by proprietary chromatographic techniques.
SF3B14 Human
Splicing Factor 3B, 14 kDa Subunit Human Recombinant
SF3B14 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 145 amino acids (1-125a.a.) and having a molecular mass of 16.7kDa. The SF3B14 is purified by proprietary chromatographic techniques.
ICOS Human
Inducible T Cell Costimulator 4 Human Recombinant
ICOS produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 362 amino acids (21-140a.a.) and having a molecular mass of 40.8kDa. (Molecular size on SDS-PAGE will appear at approximately 40-57kDa). ICOS is expressed with an 242 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
SFTPB Human
Surfactant Protein B Human Recombinant
SFTPB Human Recombinant is a single, glycosylated polypeptide chain containing 363 amino acids (25-381a.a) and having a molecular mass of 40.4kDa (calculated). SFPTB is fused to a 6 a.a on C-terminal.
HEK293 Cells.
Introduction
The term “Other” can be defined in various contexts. In a general sense, it refers to something or someone that is different or distinct from the one already mentioned or known . In biological taxonomy, classification involves organizing living organisms into hierarchical categories based on their characteristics and evolutionary history .
Biological properties of “Other” can be understood through key characteristics shared by living organisms, such as order, sensitivity or response to stimuli, reproduction, growth and development, regulation, homeostasis, and energy processing . These properties are expressed in various patterns and distributed across different tissues, contributing to the organism’s overall function and survival.
The primary biological functions of “Other” include catalyzing chemical reactions, synthesizing and repairing DNA, transporting materials across cells, receiving and sending chemical signals, responding to stimuli, and providing structural support . These functions play crucial roles in immune responses and pathogen recognition, ensuring the organism’s defense mechanisms are active and effective .
Modes of action describe the functional or anatomical changes resulting from exposure to a substance. This includes the interaction with other molecules and cells, binding partners, and downstream signaling cascades . For example, a mode of action could involve binding to DNA, leading to transcriptional regulation .
Regulatory mechanisms control the expression and activity of “Other” through transcriptional regulation and post-translational modifications . These mechanisms ensure that the biological processes are carried out efficiently and accurately, adapting to the organism’s needs and environmental changes.
In biomedical research, “Other” has various applications, including diagnostic tools and therapeutic strategies . For instance, understanding the biological properties and functions of different molecules can lead to the development of new treatments and diagnostic methods, improving healthcare outcomes.
